Clinical trial
Study to Evaluate Adverse Events and Change in Disease Activity in Participants…
NCT04888585 · AbbVie, Industry · Terminated
Key facts
| NCT number | NCT04888585 |
|---|---|
| Title | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) |
| Lead sponsor | AbbVie, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis (RA) |
| Intervention type | Drug |
| Interventions | ABBV-154, Placebo |
| Enrollment | 473 |
| Start date | Jun 23, 2021 |
| Primary completion | Aug 25, 2022 |
| Completion | Aug 4, 2023 |
| First posted | May 17, 2021 |
| Last update posted | Oct 8, 2024 |
| Countries | Australia, Canada, Czechia, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Poland and 9 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: